IMMUNOVX
LIVE

Serial Number

98089376

Owner

Banerjee, Dalfoni, G.

Attorney

Sean P. McConnell

First Use Date

Jul 23, 2023

Filing Date

Jul 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

IMMUNOVX Trademark

Serial Number: 98089376 • Registration: 8243630

IMMUNOVX is a trademark filed by Banerjee, Dalfoni, G. on July 18, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Banerjee, Dalfoni, G.

#175
Conshohocken, PA 19428

Entity Type: 01

Trademark Details

Filing Date

July 18, 2023

Registration Date

May 5, 2026

First Use Anywhere

July 23, 2023

First Use in Commerce

July 23, 2023

Published for Opposition

February 11, 2025

Goods & Services

Clinical research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development and consultation related thereto in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of new products; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific research; Scientific research consulting; Basic and clinical research in the field of respiratory science and medicine; Biochemical research and development; Consulting services for others in the field of design, planning, and implementation project management of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development; Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical research and development; Product research and development; Providing information about medical and scientific research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific research and development; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical, biologic, biotechnology, vaccine, infectious disease treatment, and adjuvant research and development

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 5, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
May 5, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 13, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 13, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 2, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 28, 2026 AITU
USE AMENDMENT FILED
Aug 25, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 25, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 8, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 22, 2025 CNSA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 21, 2025 CHAN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jan 20, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 20, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 20, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 20, 2025 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 17, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 17, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 17, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 17, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 17, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 20, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2024 CRFA
ASSIGNED TO LIE
Sep 20, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 10, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 23, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 23, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2023 NWOS
NEW APPLICATION ENTERED
Jul 21, 2023 NWAP